MedTrace Logo

Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion

NCT00905541 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2009-05-20

No results posted yet for this study

Summary

3-Hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) decrease apolipoprotein B-100-containing lipoproteins by increasing their fractional catabolic rates through low-density lipoproteins (LDL) receptor-mediated uptake. Their influence on hepatic secretion of these lipoproteins is controversial. The current study investigates whether simvastatin influences lipoprotein secretion.

Conditions

Interventions

DRUG

simvastatin

40 mg/day

DRUG

simvastatin

80 mg simvastatin acute-on-chronic

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Heiner K. Berthold, MD, PhD · University of Bonn

Study Design

Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-11-30
Primary Completion
1999-03-31
Completion
2000-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00905541 on ClinicalTrials.gov